Albumin and its application in drug delivery

Expert Opinion on Drug Delivery

Volumn 12, Issue 5, 2015, Pages 793-812

  Sleep, Darrell ^a  

^a Novozymes Biopharma DK A S   (United Kingdom)

Author keywords

Albumin; Cancer; Conjugation; Drug binding; Drug delivery; Drug development; FcRn; Fusion; Half life; Inflammation; Oncology; Pharmacokinetics

Indexed keywords

ALBUMIN RECEPTOR; CELL SURFACE RECEPTOR; DRUG CARRIER; HUMAN ALBUMIN; RECOMBINANT ALBUMIN; UNCLASSIFIED DRUG; ALBUMINOID; FC RECEPTOR; FC RECEPTOR, NEONATAL; HLA ANTIGEN CLASS 1;

ALLOSTERISM; AMINO ACID SEQUENCE; BINDING SITE; CELL VOLUME; DRUG ACCUMULATION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG MANUFACTURE; DRUG SAFETY; DRUG STABILITY; DRUG TARGETING; GENE FUSION; GENETIC ENGINEERING; HUMAN; LIGAND BINDING; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA VOLUME; PROTEIN DEGRADATION; REVIEW; ANIMAL; CHEMISTRY; HALF LIFE TIME; METABOLISM; PHARMACOKINETICS;

ALBUMINS; ANIMALS; DRUG DELIVERY SYSTEMS; HALF-LIFE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; PHARMACOKINETICS; RECEPTORS, CELL SURFACE; RECEPTORS, FC;

EID: 84928321728     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2015.993313     Document Type: Review

References (152)

1. Peters T. All about albumin: biochemistry, genetics, and medical applications. Academic Press; San Diego, CA, London: 1996
2. Throop JL, Kerl ME, Cohn LA. Albumin in health and disease: causes and-treatment of hypoalbuminemia. Comp Cont Educ Pract Vet 2004;26(12):931-9
3. Anderson CL, Chaudhury C, Kim J, et al. Perspective-FcRn transports albumin: relevance to immunology and medicine. Trends Immunol 2006;27(7):343-8
4. Kim J, Hayton WL, Robinson JM, Anderson CL. Kinetics of FcRn-mediated recycling of IgG and albumin in human: pathophysiology and therapeutic implications using a simplified mechanism-based model. Clin Immunol 2007;122(2):146-55
5. Sleep D, Cameron J, Evans LR. Albumin as a versatile platform for drug half-life extension. Biochim Biophys Acta 2013;1830(12):5526-34
6. Dockal M, Carter DC, Ruker F. The three recombinant domains of human serum albumin. Structural characterization and ligand binding properties. J Biol Chem 1999;274(41):29303-10
7. Fanali G, di Masi A, Trezza V, et al. Human serum albumin: from bench to bedside. Mol Aspects Med 2012;33(3):209-90
8. Dockal M, Carter DC, Ruker F. Conformational transitions of the three recombinant domains of human serum albumin depending on pH. J Biol Chem 2000;275(5):3042-50
9. Ghuman J, Zunszain PA, Petitpas I, et al. Structural basis of the drug-binding specificity of human serum albumin. J Mol Biol 2005;353(1):38-52
10. Gundry RL, Fu Q, Jelinek CA, et al. Investigation of an albumin-enriched fraction of human serum and its albuminome. Proteomics Clin Appl 2007;1(1):73-88
11. Fasano M, Curry S, Terreno E, et al. The extraordinary ligand binding properties of human serum albumin. IUBMB Life 2005;57(12):787-96
12. Yamasaki K, Chuang VT, Maruyama T, Otagiri M. Albumin-drug interaction and its clinical implication. Biochim Biophys Acta 2013;1830(12):5435-43
13. Ha CE, Bhagavan NV. Novel insights into the pleiotropic effects of human serum albumin in health and disease. Biochim Biophys Acta 2013;1830(12):5486-93
14. Varshney A, Sen P, Ahmad E, et al. Ligand binding strategies of human serum albumin: how can the cargo be utilized? Chirality 2010;22(1):77-87
15. Bal W, Sokolowska M, Kurowska E, Faller P. Binding of transition metal ions to albumin: sites, affinities and rates. Biochim Biophys Acta 2013;1830(12):5444-55
16. Stewart AJ, Blindauer CA, Berezenko S, et al. Role of Tyr84 in controlling the reactivity of Cys34 of human albumin. FEBS J 2005;272(2):353-62
17. Ishima Y, Kragh-Hansen U, Maruyama T, Otagiri M. Albumin as a nitric oxide-traffic protein: characterization, biochemistry and possible future therapeutic applications. Drug Metab Pharmacokinet 2009;24(4):308-17
18. Hamilton JA. NMR reveals molecular interactions and dynamics of fatty acid binding to albumin. Biochim Biophys Acta 2013;1830(12):5418-26
19. Curry S, Mandelkow H, Brick P, Franks N. Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites. Nat Struct Biol 1998;5(9):827-35
20. Bhattacharya AA, Grune T, Curry S. Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin. J Mol Biol 2000;303(5):721-32
21. Fujiwara S, Amisaki T. Fatty acid binding to serum albumin: molecular simulation approaches. Biochim Biophys Acta 2013;1830(12):5427-34
22. Saifer A, Goldman L. The free fatty acids bound to human serum albumin. J Lipid Res 1961;2(3):268-70
23. Merlot AM, Kalinowski DS, Richardson DR. Unraveling the mysteries of serum albumin-more than just a serum protein. Front Physiol 2014;5:299
24. Gradishar WJ. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother 2006;7(8):1041-53
25. Malik AB. Targeting endothelial cell surface receptors: novel mechanisms of microvascular endothelial barrier transport. J Med Sci 2009;2(1):13-17
26. Amsellem S, Gburek J, Chamard G, et al. Cubilin is essential for albumin reabsorption in the renal proximal tubule. J Am Soc Nephrol 2010;21:1859-67
27. Saito A, Sato H, Lino N, et al. Molecular mechanisms of receptor-mediated endocytosis in the renal proximal tubular epithelium. J Biomed Biotechnol 2010;2010:403272
28. Chaudhury C, Mehnaz S, Robinson JM, et al. The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J Exp Med 2003;197(3):315-22
29. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007;7(9):715-25
30. Andersen JT, Sandlie I. The versatile MHC class I-related FcRn protects IgG and albumin from degradation: implications for development of new diagnostics and therapeutics. Drug Metab Pharmacokinet 2009;24(4):318-32
31. Baker K, Qiao SW, Kuo T, et al. Immune and non-immune functions of the (not so) neonatal Fc receptor. FcRn. Semin Immunopathol 2009;31(2):223-36
32. Kuo TT, Baker K, Yoshida M, et al. Neonatal Fc receptor: from immunity to therapeutics. J Clin Immunol 2010;30(6):777-89
33. Roopenian DC, Sun VZ. Clinical ramifications of the MHC family Fc receptor FcRn. J Clin Immunol 2010;30(6):790-7
34. Chaudhury C, Brooks CL, Carter DC, et al. Albumin binding to FcRn: distinct from the FcRn-IgG interaction. Biochemistry 2006;45(15):4983-90
35. Rath T, Kuo TT, Baker K, et al. The immunologic functions of the neonatal Fc receptor for IgG. J Clin Immunol 2013;33(Suppl 1)):S9-17
36. Simister NE, Mostov KE. An Fc receptor structurally related to MHC class I antigens. Nature 1989;337(6203):184-7
37. Burmeister WP, Gastinel LN, Simister NE, et al. Crystal structure at 2.2 A resolution of the MHC-related neonatal Fc receptor. Nature 1994;372(6504):336-43
38. West AP Jr, Bjorkman PJ. Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor. Biochemistry 2000;39(32):9698-708
39. Gastinel LN, Simister NE, Bjorkman PJ. Expression and crystallization of a soluble and functional form of an Fc receptor related to class I histocompatibility molecules. Proc Natl Acad Sci USA 1992;89(2):638-42
40. Wani MA, Haynes LD, Kim J, et al. Familial hypercatabolic hypoproteinemia caused by deficiency of the neonatal Fc receptor, FcRn, due to a mutant beta2-microglobulin gene. Proc Natl Acad Sci USA 2006;103(13):5084-9
41. Waldmann TA, Terry WD. Familial hypercatabolic hypoproteinemia. A disorder of endogenous catabolism of albumin and immunoglobulin. J Clin Invest 1990;86(6):2093-8
42. Andersen JT, Daba MB, Berntzen G, et al. Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding. J Biol Chem 2010;285(7):4826-36
43. Andersen JT, Dalhus B, Cameron J, et al. Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor. Nat Comm 2012;3:610
44. Schmidt MM, Townson SA, Andreucci AJ, et al. Crystal structure of an HSA/FcRn complex reveals recycling by competitive mimicry of HSA ligands at a pH-dependent hydrophobic interface. Structure 2013;21(11):1966-78
45. Sand KM, Dalhus BO, Christianson GJ, et al. Dissection of the FcRn-albumin interface using mutagenesis and anti-FcRn albumin blocking antibodies. J Biol Chem 2014;289:p17228-39
46. Oganesyan V, Damschroder MM, Cook KE, et al. Structural insights into neonatal Fc receptor-based recycling mechanisms. J Biol Chem 2014;289(11):7812-24
47. Andersen JT, Dalhus B, Viuff D, et al. Extending serum half-life of albumin by engineering neonatal Fc receptor (FcRn) binding. J Biol Chem 2014;289(19):13492-502
48. Kragh-Hansen U, Minchiotti L, Galliano M, Peters T Jr. Human serum albumin isoforms: genetic and molecular aspects and functional consequences. Biochim Biophys Acta 2013;1830(12):5405-17
49. Minchiotti L, Galliano M, Kragh-Hansen U, Peters T Jr. Mutations and polymorphisms of the gene of the major human blood protein, serum albumin. Hum Mutat 2008;29(8):1007-16
50. Bosse D, Praus M, Kiessling P, et al. Phase I comparability of recombinant human albumin and human serum albumin. J Clin Pharmacol 2005;45(1):57-67
51. Sansonno DE, DeTomaso P, Papanice MA, Manghisi OG. An enzyme-linked immunosorbent assay for the detection of autoantibodies to albumin. J Immunol Meth 1986;90(1):131-6
52. Gregor I, Iberg N, Berger W, Fluckiger R. Albumin-directed antibodies in diabetes: demonstration of human serum albumin-directed IgM autoantibodies. Diabetologia 1986;29(8):481-4
53. Baraldini M, Miglio F, Cursaro C, et al. Clinical significance of antibodies to polymerized human albumin detected by enzyme-linked immunosorbent assay. Ric Clin Lab 1988;18(4):291-300
54. Chapman J, Maayan C, Michaelson DM. Antibodies to human serum albumin in familial dysautonomia. Int Arch Allergy Imm 1993;100(1):42-6
55. Pires ES, Parte PP, Meherji PK, et al. Naturally occurring anti-albumin antibodies are responsible for false positivity in diagnosis of autoimmune premature ovarian failure. J Histochem Cytochem 2006;54(4):397-405
56. Khan MW, Qadrie ZL, Khan WA. Antibodies against gluco-oxidatively modified human serum albumin detected in diabetes-associated complications. Int Arch Allergy Imm 2010;153(2):207-14
57. Sjowall C, Kastbom A, Almroth G, et al. Beware of antibodies to dietary proteins in "antigen-specific" immunoassays! falsely positive anticytokine antibody tests due to reactivity with bovine serum albumin in rheumatoid arthritis (the Swedish TIRA project). J Rheumatol 2011;38(2):215-20
58. Chen Z, He Y, Shi B, Yang D. Human serum albumin from recombinant DNA technology: challenges and strategies. Biochim Biophys Acta 2013;1830(12):5515-25
59. Dodsworth N, Harris R, Denton K, et al. Comparative studies of recombinant human albumin and human serum albumin derived by blood fractionation. Biotechnol Appl Biochem 1996;24(Pt 2):171-6
60. Kobayashi K. Summary of recombinant human serum albumin development. Biologicals 2006;34(1):55-9
61. Blindauer CA, Harvey I, Bunyan KE, et al. Structure, properties, and engineering of the major zinc binding site on human albumin. J Biol Chem 2009;284(34):23116-24
62. Komatsu T, Ohmichi N, Nakagawa A, et al. O2 and CO binding properties of artificial hemoproteins formed by complexing iron protoporphyrin IX with human serum albumin mutants. J Am Chem Soc 2005;127(45):15933-42
63. Iwao Y, Hiraike M, Kragh-Hansen U, et al. Altered chain-length and glycosylation modify the pharmacokinetics of human serum albumin. Biochim Biophys Acta 2009;1794(4):634-41
64. Sheffield WP, Marques JA, Bhakta V, Smith IJ. Modulation of clearance of recombinant serum albumin by either glycosylation or truncation. Thromb Res 2000;99(6):613-21
65. Nakajou K, Watanabe H, Kragh-Hansen U, et al. The effect of glycation on the structure, function and biological fate of human serum albumin as revealed by recombinant mutants. Biochim Biophys Acta 2003;1623(2-3):88-97
66. Iwao Y, Anraku M, Yamasaki K, et al. Oxidation of Arg-410 promotes the elimination of human serum albumin. Biochim Biophys Acta 2006;1764(4):743-9
67. Iwao Y, Hiraike M, Kragh-Hansen U, et al. Changes of net charge and alpha-helical content affect the pharmacokinetic properties of human serum albumin. Biochim Biophys Acta 2007;1774(12):1582-90
68. Schnitzer JE, Sung A, Horvat R, Bravo J. Preferential interaction of albumin-binding proteins, gp30 and gp18, with conformationally modified albumins. Presence in many cells and tissues with a possible role in catabolism. J Biol Chem 1992;267(34):24544-53
69. Schnitzer JE, Bravo J. High affinity binding, endocytosis, and degradation of conformationally modified albumins. Potential role of gp30 and gp18 as novel scavenger receptors. J Biol Chem 1993;268(10):7562-70
70. Elsadek B, Kratz F. Impact of albumin on drug delivery-new applications on the horizon. J Control Release 2012;157(1):4-28
71. Kratz F, Elsadek B. Clinical impact of serum proteins on drug delivery. J Control Release 2012;161(2):429-45
72. Trussel S, Dumelin C, Frey K, et al. New strategy for the extension of the serum half-life of antibody fragments. Bioconjug Chem 2009;20(12):2286-92
73. Zobel K, Koehler MF, Beresini MH, et al. Phosphate ester serum albumin affinity tags greatly improve peptide halflife in vivo. Bioorg Med Chem Lett 2003;13(9):1513-15
74. Home P, Kurtzhals P. Insulin detemir: from concept to clinical experience. Expert Opin Pharmacol 2006;7(3):325-43
75. Kurtzhals P, Havelund S, Jonassen I, et al. Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem J 1995;312(Pt 3):725-31
76. Gough SC, Harris S, Woo V, Davies M. Insulin degludec: overview of a novel ultra long-acting basal insulin. Diabetes Obes metab 2013;15(4):301-9
77. Bode B. An overview of the pharmacokinetics, efficacy and safety of liraglutide. Diabetes Res Clin Pr 2012;97(1):27-42
78. Rigato M, Fadini GP. Comparative effectiveness of liraglutide in the treatment of type 2 diabetes. Diabetes Metab Syndr Obes 2014;7:107-20
79. Ryan GJ, Foster KT, Jobe LJ. Review of the therapeutic uses of liraglutide. Clin Ther 2011;33(7):793-811
80. Gotfredsen CF, Molck AM, Thorup I, et al. The human GLP-1 analogs liraglutide and semaglutide: absence of histopathological effects on the pancreas in nonhuman primates. Diabetes 2014;63(7):2486-97
81. Zheng YR, Suntharalingam K, Johnstone TC, et al. Pt(IV) prodrugs designed to bind non-covalently to human serum albumin for drug delivery. J Am Chem Soc 2014;136(24):8790-8
82. Walker A, Dunlevy G, Topley P. Albumin-binding fusion proteins in the development of novel long-acting therapeutics. In: Schmidt SR, editor. Fusion protein technologies for biopharmaceuticals. Wiley, New Jersey, USA; 2013. p. 179-90
83. Jonsson A, Dogan J, Herne N, et al. Engineering of a femtomolar affinity binding protein to human serum albumin. Protein Eng Des Sel 2008;21(8):515-27
84. Nilvebrant J, Hober S. The albumin-binding domain as a scaffold for protein engineering. Comput Struct Biotechnol J 2013;6:e201303009
85. Angelini A, Morales-Sanfrutos J, Diderich P, et al. Bicyclization and tethering to albumin yields long-acting peptide antagonists. J Med Chem 2012;55(22):10187-97
86. Dennis MS, Zhang M, Meng YG, et al. Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J Biol Chem 2002;277(38):35035-43
87. II, Nguyen A, Reyes AEZhang M, et al. The pharmacokinetics of an albumin-binding Fab (AB.Fab) can be modulated as a function of affinity for albumin. Protein Eng Des Sel 2006;19(7):291-7
88. Holt LJ, Basran A, Jones K, et al. Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs. Protein Eng Des Sel 2008;21(5):283-8
89. Tijink BM, Laeremans T, Budde M, et al. Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology. Mol Cancer Ther 2008;7(8):2288-97
90. Roovers RC, Laeremans T, Huang L, et al. Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies. Cancer Immunol Immunother 2007;56(3):303-17
91. Lipovsek D. Adnectins: engineered target-binding protein therapeutics. Protein Eng Des Sel 2011;24(1-2):3-9
92. Levy OE, Jodka CM, Ren SS, et al. Novel exenatide analogs with peptidic albumin binding domains: potent anti-diabetic agents with extended duration of action. PLoS One 2014;9(2):e87704
93. Paige AG, Whitcomb KL, Liu J, Kinstler O. Prolonged circulation of recombinant human granulocyte-colony stimulating factor by covalent linkage to albumin through a heterobifunctional polyethylene glycol. Pharm Res 1995;12(12):1883-8
94. Leger R, Benquet C, Huang X, et al. Kringle 5 peptide-albumin conjugates with anti-migratory activity. Bioorg Med Chem Lett 2004;14(4):841-5
95. Simon M, Frey R, Zangemeister-Wittke U, Pluckthun A. Orthogonal assembly of a designed ankyrin repeat protein-cytotoxin conjugate with a clickable serum albumin module for half-life extension. Bioconjug Chem 2013;24(11):1955-66
96. Stoddart CA, Nault G, Galkina SA, et al. Albumin-conjugated C34 peptide HIV-1 fusion inhibitor: equipotent to C34 and T-20 in vitro with sustained activity in SCID-hu Thy/Liv mice. J Biol Chem 2008;283(49):34045-52
97. Thibaudeau K, Leger R, Huang X, et al. Synthesis and evaluation of insulinhuman serum albumin conjugates. Bioconjug Chem 2005;16(4):1000-8
98. Holmes DL, Thibaudeau K, L'Archeveque B, et al. Site specific 1:1 opioid:albumin conjugate with in vitro activity and long in vivo duration. Bioconjug Chem 2000;11(4):439-44
99. Ehrlich GK, Michel H, Truitt T, et al. Preparation and characterization of albumin conjugates of a truncated peptide YY analogue for half-life extension. Bioconjug Chem 2013;24(12):2015-24
100. Giannoukakis N. CJC-1131. Conju Chem Curr Opin Investig Drugs 2003;4(10):1245-9
101. Kim JG, Baggio LL, Bridon DP, et al. Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo. Diabetes 2003;52(3):751-9
102. Leger R, Thibaudeau K, Robitaille M, et al. Identification of CJC-1131-albumin bioconjugate as a stable and bioactive GLP-1(7-36) analog. Bioorg Med Chem Lett 2004;14(17):4395-8
103. Baggio LL, Huang Q, Cao X, Drucker DJ. An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis. Gastroenterology 2008;134(4):1137-47
104. Weimer T, Metzner HJ, Schulte S. Recombinant albumin fusion proteins. In: Schmidt SR, editor. Fusion protein technologies for biopharmaceuticals. Wiley; 2013. p. 163-78
105. Shi S, Liu J, Joshi SB, et al. Biophysical characterization and stabilization of the recombinant albumin fusion protein sEphB4-HSA. J Pharm Sci 2012;101(6):1969-84
106. Cordes AA, Carpenter JF, Randolph TW. Selective domain stabilization as a strategy to reduce human serum albumin-human granulocyte colony stimulating factor aggregation rate. J Pharm Sci 2012;101(6):2009-16
107. Cordes AA, Platt CW, Carpenter JF, Randolph TW. Selective domain stabilization as a strategy to reduce fusion protein aggregation. J Pharm Sci 2012;101(4):1400-9
108. Rustgi VK. Albinterferon alfa-2b, a novel fusion protein of human albumin and human interferon alfa-2b, for chronic hepatitis C. Curr Med Res Opin 2009;25(4):991-1002
109. EMA. European public assessment report for albigluide. 2014. Available from: http://www.ema. europa.eu/docs/en-GB/document-library/EPAR---Public-assessment-report/human/002735/WC500165119.pdf [Cited 23 January 2014]
110. Woodward HN, Anderson SL. Once-weekly albiglutide in the management of type 2 diabetes: patient considerations. Patient Prefer Adherence 2014;8:789-803
111. Teva Biopharmaceuticals USA, Inc. Recombinant human-albumin human granulocyte colony stimulating factor for the prevention of neutropenia. WO2010083439; 2010
112. Cousens LP, Najafian N, Mingozzi F, et al. In vitro and in vivo studies of IgG-derived Treg epitopes (Tregitopes): a promising new tool for tolerance induction and treatment of autoimmunity. J Clin Immunol 2013;33(Suppl 1):S43-9
113. DeGroot AS. Do Tregitpes have the potential to impact the current treatment landscape of autoimmune diseases? Expert Rev Clin Immunol 2013;9(12):1155-7
114. Sleep D. Veltis® -Engineered albumins for optimized drug dosing. 2014. Available from: http://www.slideshare.net/NiklasAndersson6/novozymes-veltis-an-innovative-platform-technology-for-the-half-life-extension-of-biotherapeutics-2014-april [Cited 9 December 2014]
115. Neumann E, Frei E, Funk D, et al. Native albumin for targeted drug delivery. Expert Opin Drug Deliv 2010;7(8):915-25
116. Yewale C, Baradia D, Vhora I, Misra A. Proteins: emerging carrier for delivery of cancer therapeutics. Expert Opin Drug Deliv 2013;10(10):1429-48
117. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 2008;132(3):171-83
118. Stehle G, Sinn H, Wunder A, et al. Plasma protein (albumin) catabolism by the tumor itself-implications for tumor metabolism and the genesis of cachexia. Crit Rev Oncol Hematol 1997;26(2):77-100
119. Kratz F. A clinical update of using albumin as a drug vehicle-A commentary. J Control Release 2014;90:331-6
120. Said N, Frierson HF, Sanchez-Carbayo M, et al. Loss of SPARC in bladder cancer enhances carcinogenesis and progression. J Clin Invest 2013;123(2):751-66
121. Cardone RA, Casavola V, Reshkin SJ. The role of disturbed pH dynamics and the Na? exchanger in metastasis. Nat Rev Cancer 2005;5(10):786-95
122. Kremer P, Wunder A, Sinn H, et al. Laser-induced fluorescence detection of malignant gliomas using fluorescein-labeled serum albumin: experimental and preliminary clinical results. Neurol Res 2000;22(5):481-9
123. Ding R, Frei E, Fardanesh M, et al. Pharmacokinetics of 5-aminofluorescein-albumin, a novel fluorescence marker of brain tumors during surgery. J Clin Pharmacol 2011;51(5):672-8
124. Ishima Y, Chen D, Fang J, et al. S-Nitrosated human serum albumin dimer is not only a novel anti-tumor drug but also a potentiator for antitumor drugs with augmented EPR effects. Bioconjug Chem 2012;23(2):264-71
125. Ishima Y, Kragh-Hansen U, Maruyama T, Otagiri M. Poly-s-nitrosated albumin as a safe and effective multifunctional antitumor agent: characterization, biochemistry and possible future therapeutic applications. BioMed Res Int 2013;2013:353892
126. Stehle G, Sinn H, Wunder A, et al. The loading rate determines tumor targeting properties of methotrexate-albumin conjugates in rats. Anticancer Drugs 1997;8(7):677-85
127. Warnecke A, Fichtner I, Sass G, Kratz F. Synthesis, cleavage profile, and antitumor efficacy of an albumin-binding prodrug of methotrexate that is cleaved by plasmin and cathepsin B. Arch Pharm (WeimHeim) 2007;340(8):389-95
128. Fiehn C, Kratz F, Sass G, et al. Targeted drug delivery by in vivo coupling to endogenous albumin: an albumin-binding prodrug of methotrexate (MTX) is better than MTX in the treatment of murine collagen-induced arthritis. Ann Rheum Dis 2008;67(8):1188-91
129. Mita MM, Natale RB, Wolin EM, et al. Pharmacokinetic study of aldoxorubicin in patients with solid tumors. Invest New Drugs 2014. [Epub ahead of print]
130. Singla AK, Garg A, Aggarwal D. Paclitaxel and its formulations. Int J Pharm 2002;235(1-2):179-92
131. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001;37(13):1590-8
132. Socinski MA, Bondarenko I, Karaseva NA, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol 2012;30(17):2055-62
133. Lluch A, Alvarez I, Munoz M, et al. Treatment innovations for metastatic breast cancer: nanoparticle albumin-bound (NAB) technology targeted to tumors. Crit Rev Oncol Hematol 2014;89(1):62-72
134. Al-Batran SE, Geissler M, Seufferlein T, Oettle H. Nab-paclitaxel for metastatic pancreatic cancer: clinical outcomes and potential mechanisms of action. Oncol Res Treat 2014;37(3):128-34
135. Cecco S, Aliberti M, Baldo P, et al. Safety and efficacy evaluation of albumin-bound paclitaxel. Expert Opin Drug Saf 2014;13(4):511-20
136. Kudlowitz D, Muggia F. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel): extending its indications. Expert Opin Drug Saf 2014;13(6):681-5
137. Desai N. Challenges in development of nanoparticle-based therapeutics. AAPS J 2012;14(2):282-95
138. Li C, Li Y, Gao Y, et al. Direct comparison of two albumin-based paclitaxel-loaded nanoparticle formulations: is the crosslinked version more advantageous? Int J Pharm 2014;468(1-2):15-25
139. Byeon HJ, Min SY, Kim I, et al. Human serum albumin-TRAIL conjugate for the treatment of rheumatoid arthritis. Bioconjug Chem 2014. [Epub ahead of print]
140. Liu M, Huang Y, Hu L, et al. Selective delivery of interleukine-1 receptor antagonist to inflamed joint by albumin fusion. BMC Biotechnol 2012;12:68
141. Pang Z, Gao H, Chen J, et al. Intracellular delivery mechanism and brain delivery kinetics of biodegradable cationic bovine serum albumin-conjugated polymersomes. Int J Nanomedicine 2012;7:3421-32
142. Fiume L, Di Stefano G. Lactosaminated human albumin, a hepatotropic carrier of drugs. Eur J Pharm Sci 2010;40(4):253-62
143. Danhier F, Le Breton A, Preat V. RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. Mol Pharm 2012;9(11):2961-73
144. Temming K, Meyer DL, Zabinski R, et al. Evaluation of RGD-targeted albumin carriers for specific delivery of auristatin E to tumor blood vessels. Bioconjug Chem 2006;17(6):1385-94
145. Temming K, Meyer DL, Zabinski R, et al. Improved efficacy of alphavbeta3-targeted albumin conjugates by conjugation of a novel auristatin derivative. Mol Pharm 2007;4(5):686-94
146. Yazaki PJ, Kassa T, Cheung CW, et al. Biodistribution and tumor imaging of an anti-CEA single-chain antibody-albumin fusion protein. Nucl Med Bio 2008;35(2):151-8
147. Huhalov A, Graff C, Wittrup KD, et al. HSAbodies: a new class of engineered antibody-based molecules for targeting cancer. Bri J Cancer 2004;91:S63
148. Altintas I, Heukers R, van der Meel R, et al. Nanobody-albumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells. J Control Release 2013;165(2):110-18
149. Ji S, Xu J, Zhang B, et al. RGD-conjugated albumin nanoparticles as a novel delivery vehicle in pancreatic cancer therapy. Cancer Bio Ther 2012;13(4):206-15
150. Mei B, Low SC, Krassova S, et al. Monomeric Fc-fusion proteins. In: Schmidt SR, editor. Fusion protein technologies for biopharmaceuticals. Wiley, New Jersey, USA; 2013. p. 107-21
151. Pridgen EM, Alexis F, Kuo TT, et al. Transepithelial transport of Fc-targeted nanoparticles by the neonatal Fc receptor for oral delivery. Sci Transl Med 2013;5(213):213ra167
152. Ye L, Zeng R, Bai Y, et al. Efficient mucosal vaccination mediated by the neonatal Fc receptor. Nat Biotechnol 2011;29(2):158-63